Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mapping bladder cancer care: a nationwide look at Real-World treatment

NCT ID NCT07784387

Knowledge-focused Sponsor: Janssen-Cilag Farmaceutica Ltda. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study looks back at medical records of 250 people in Portugal diagnosed with high-risk non-muscle-invasive bladder cancer between 2016 and 2020. The goal is to see how these patients are actually diagnosed, treated, and followed in everyday practice—including which surgeries, therapies like BCG, chemotherapy, or immunotherapy they receive. By understanding real-world care patterns, researchers hope to spot gaps and opportunities to improve outcomes for this early-stage but aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could help identify gaps and variations in bladder cancer care, potentially guiding better treatment strategies and improving patient outcomes.
What could go wrong
As a retrospective study, it relies on existing records and cannot prove cause-and-effect. Findings may not apply beyond Portugal or the specific time period reviewed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes the participants from Portuguese hospitals that treat and manage High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in routine clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Bladder cancer diagnosis between January 1, 2016 and December 31, 2020 * Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue) * Minimal follow-up time of 5 years unless there is premature death event Exclusion criteria: * Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1 * History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC * Participation in any interventional clinical trial during the observation period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary bladder neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urinary bladder neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ipo Lisboa

    RECRUITING

    Lisbon, 1099-023, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.